↓ Skip to main content

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application

Overview of attention for article published in Journal of Hematology & Oncology, November 2013
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
26 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application
Published in
Journal of Hematology & Oncology, November 2013
DOI 10.1186/1756-8722-6-83
Pubmed ID
Authors

Federico Pozzo, Michele Dal Bo, Nadia Peragine, Riccardo Bomben, Antonella Zucchetto, Francesca Maria Rossi, Massimo Degan, Davide Rossi, Annalisa Chiarenza, Alberto Grossi, Francesco Di Raimondo, Francesco Zaja, Gabriele Pozzato, Paola Secchiero, Gianluca Gaidano, Giovanni Del Poeta, Giorgio Zauli, Robin Foà, Anna Guarini, Valter Gattei

Abstract

TP53 defects, i.e., 17p13 deletion and/or nucleotide mutations, associate with short survival and chemorefractoriness in chronic lymphocytic leukemia (CLL). In this context, since direct sequencing of the TP53 gene does not evaluate TP53 functionality, a functional assessment of TP53 pathway may be of interest to identify high risk CLL. By taking advantage of a training cohort of 100 CLL and a validation cohort of 40 CLL with different patterns of TP53 mutation/deletion by FISH and sequencing, we propose an in-vitro assay in which the modulation of TP53 protein and CDKN1A mRNA were investigated upon 24-hour exposure of CLL cells to Nutlin-3.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 26 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 27%
Student > Ph. D. Student 4 15%
Other 3 12%
Student > Doctoral Student 2 8%
Student > Bachelor 2 8%
Other 4 15%
Unknown 4 15%
Readers by discipline Count As %
Agricultural and Biological Sciences 7 27%
Medicine and Dentistry 6 23%
Biochemistry, Genetics and Molecular Biology 5 19%
Immunology and Microbiology 3 12%
Neuroscience 1 4%
Other 0 0%
Unknown 4 15%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 November 2013.
All research outputs
#20,209,145
of 22,729,647 outputs
Outputs from Journal of Hematology & Oncology
#1,033
of 1,189 outputs
Outputs of similar age
#187,645
of 215,386 outputs
Outputs of similar age from Journal of Hematology & Oncology
#13
of 14 outputs
Altmetric has tracked 22,729,647 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,189 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 215,386 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.